Join the Ovarian Cancer group to help and get support from people like you.
Ovarian Cancer News
Related terms: Cancer, Ovarian, Cancer, Ovaries
Risk for Ovarian Cancer Increased for Women With Endometriosis
THURSDAY, July 18, 2024 – Women with endometriosis have an increased risk of ovarian cancer, with the highest risk seen for women with deep infiltrating endometriosis and/or ovarian endometriomas,...
Endometriosis Linked to Four-fold Higher Odds for Ovarian Cancer
THURSDAY, July 18, 2024 – Women who struggle with endometriosis may be vulnerable to another health danger: New research shows they are about four times more likely to develop ovarian cancer than...
Premenopausal Bilateral Oophorectomy Before Age 40 Affects Brain White Matter
TUESDAY, July 9, 2024 – Women who undergo premenopausal bilateral oophorectomy (PBO) before age 40 years have reduced brain white matter integrity in later life, according to a study published...
FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE) June 28, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has app...
J&J Settles Talcum Powder Lawsuits From States for $700 Million
THURSDAY, June 13, 2024 – Johnson & Johnson will pay $700 million to settle claims from 42 states and the District of Columbia that the company continued to market its talcum powder products even as...
ENDO: Early Menopause Tied to Heightened Risk for Breast, Ovarian Cancer
TUESDAY, June 11, 2024 – Women with early menopause have a two times greater risk for breast cancer and a nearly four times higher risk for ovarian cancer, according to a study presented at the...
Very Early Menopause Could Raise Odds for Breast, Ovarian Cancers
TUESDAY, June 4, 2024 – Menopause before the age of 40 could raise a woman's long-term risk for breast or ovarian cancers, new research suggests. Besides that, "there is also higher risk of breast,...
ASCO: Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer
TUESDAY, May 28, 2024 – Conjugated equine estrogen (CEE) taken alone for menopause may increase the risk for developing and dying from ovarian cancer, according to a study presented at the annual...
Genital Talc Use Positively Linked to Ovarian Cancer
TUESDAY, May 21, 2024 – There is a positive association between use of intimate care products, including genital talc, and ovarian cancer, according to a study published online May 15 in the Journal...
Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits
THURSDAY, May 2, 2024 – Johnson & Johnson announced Wednesday that it would pay out more than $6.5 billion over the next 25 years to settle existing lawsuits claiming that its talc-containing...
AI May Bring a Better Blood Test for Ovarian Cancer
WEDNESDAY, April 10, 2024 – Using AI to track fragments of tumor-associated DNA in the blood, scientists say they may be close to an accurate test for a silent killer: Ovarian cancer. It's the fifth...
U.S. Food and Drug Administration (FDA) Grants Full Approval for Elahere (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
The full approval of Elahere is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, ...
Early Diagnosis of High-Grade Serous Ovarian Cancer Feasible
MONDAY, Dec. 11, 2023 – Early diagnosis of high-grade serous ovarian cancer (HGSOC) seems feasible through analysis of genomic alterations in DNA from Papanicolaou (Pap) test smears, according to a...
White Women Overrepresented in Gynecologic Cancer Trials
TUESDAY, Dec. 12, 2023 – White women are disproportionately represented in clinical trials for gynecologic cancers, according to a study published online Dec. 7 in JAMA Network Open. Wafa Khadraoui, ...
Mirvetuximab Soravtansine-Gynx Beneficial for FRα-Positive Ovarian Cancer
THURSDAY, Dec. 7, 2023 – For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a...
Ask a question
To post your own question to this support group, sign in or create an account.